TW317500B - - Google Patents
Download PDFInfo
- Publication number
- TW317500B TW317500B TW084106619A TW84106619A TW317500B TW 317500 B TW317500 B TW 317500B TW 084106619 A TW084106619 A TW 084106619A TW 84106619 A TW84106619 A TW 84106619A TW 317500 B TW317500 B TW 317500B
- Authority
- TW
- Taiwan
- Prior art keywords
- pancreatitis
- compound
- pancreatic
- therapeutic composition
- present
- Prior art date
Links
- 206010033645 Pancreatitis Diseases 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 15
- -1 diester compound Chemical class 0.000 claims abstract description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
- 229910014033 C-OH Inorganic materials 0.000 claims 1
- 229910014570 C—OH Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 23
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 12
- GGLZPLKKBSSKCX-YFKPBYRVSA-N L-ethionine Chemical compound CCSCC[C@H](N)C(O)=O GGLZPLKKBSSKCX-YFKPBYRVSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000002689 soil Substances 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- VIHIKSJKXIMMLV-FZTHFCCHSA-M potassium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-5-oxo-2h-furan-4-yl] [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] phosphate Chemical compound [K+].C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OP([O-])(=O)OC1=C(O)[C@@H]([C@@H](O)CO)OC1=O VIHIKSJKXIMMLV-FZTHFCCHSA-M 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100037611 Lysophospholipase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010058864 Phospholipases A2 Proteins 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
- 101100087393 Caenorhabditis elegans ran-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 241001516485 Cypripedium Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001437 anti-cataract Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000008400 supply water Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18428294 | 1994-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW317500B true TW317500B (OSRAM) | 1997-10-11 |
Family
ID=16150598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW084106619A TW317500B (OSRAM) | 1994-08-05 | 1995-06-28 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5650404A (OSRAM) |
| EP (1) | EP0699440B1 (OSRAM) |
| KR (1) | KR960006915A (OSRAM) |
| AT (1) | ATE173626T1 (OSRAM) |
| CA (1) | CA2152693A1 (OSRAM) |
| DE (1) | DE69506197T2 (OSRAM) |
| ES (1) | ES2124477T3 (OSRAM) |
| TW (1) | TW317500B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6703384B2 (en) * | 1998-09-23 | 2004-03-09 | Research Development Foundation | Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof |
| CN1195513C (zh) * | 1998-09-23 | 2005-04-06 | 研究发展基金会 | 生良酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途 |
| CN1243000C (zh) * | 2000-02-11 | 2006-02-22 | 研究发展基金会 | 生育酚、生育三烯酚、其它苯并二氢吡喃和侧链衍生物,及其用途 |
| WO2002026238A1 (en) * | 2000-09-26 | 2002-04-04 | Vital Health Sciences Pty Ltd. | Phosphate derivative supplements |
| AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
| JP4745608B2 (ja) | 2001-07-27 | 2011-08-10 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | 電子伝達剤のリン酸誘導体を用いた皮膚治療 |
| US20030236301A1 (en) * | 2001-12-19 | 2003-12-25 | Bob Sanders | Liposomal delivery of vitamin E based compounds |
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| NZ549567A (en) | 2004-03-03 | 2009-10-30 | Vital Health Sciences Pty Ltd | Formulations comprising a tocopheryl phosphate tertiary amine alkaloid complex |
| ES2557475T3 (es) | 2005-06-17 | 2016-01-26 | Vital Health Sciences Pty Ltd. | Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones |
| WO2007070981A1 (en) * | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd | Compounds having cytokine modulating properties |
| US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| ES2829386T3 (es) | 2010-03-30 | 2021-05-31 | Phosphagenics Ltd | Parche de administración transdérmica |
| RU2425669C1 (ru) * | 2010-04-13 | 2011-08-10 | Общество С Ограниченной Ответственностью "Гамаветфарм" | Средство для профилактики и лечения острого и хронического панкреатита |
| EP2685992A4 (en) | 2011-03-15 | 2014-09-10 | Phosphagenics Ltd | AMINOCHINOLINE AS A KINASEHEMMER |
| ES2981002T3 (es) | 2015-12-09 | 2024-10-04 | Avecho Biotechnology Ltd | Formulación farmacéutica |
| JP7198754B2 (ja) | 2016-12-21 | 2023-01-04 | アベーチョ バイオテクノロジー リミテッド | 方法 |
| EP4034137A4 (en) * | 2019-09-27 | 2023-09-20 | Duke University | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF PANCREATITIS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59219295A (ja) * | 1983-05-30 | 1984-12-10 | Senjiyu Seiyaku Kk | リン酸ジエステルまたはその塩およびそれらの製造法 |
| JPS62145019A (ja) * | 1985-12-19 | 1987-06-29 | Senjiyu Seiyaku Kk | 抗炎症剤 |
| JPS62205091A (ja) * | 1986-03-04 | 1987-09-09 | Senjiyu Seiyaku Kk | 新規なリン酸ジエステルならびにその塩、その製造法およびそれを含有する製剤 |
| JP2526059B2 (ja) * | 1987-04-28 | 1996-08-21 | 千寿製薬株式会社 | 抗潰瘍剤 |
| PH25859A (en) * | 1988-01-11 | 1991-12-02 | Takeda Chemical Industries Ltd | Composition for treatment of ischemic disorder |
| JP2854631B2 (ja) * | 1989-11-21 | 1999-02-03 | 千寿製薬株式会社 | 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤 |
-
1995
- 1995-06-27 CA CA002152693A patent/CA2152693A1/en not_active Abandoned
- 1995-06-28 TW TW084106619A patent/TW317500B/zh active
- 1995-07-18 US US08/503,722 patent/US5650404A/en not_active Expired - Fee Related
- 1995-08-01 DE DE69506197T patent/DE69506197T2/de not_active Expired - Fee Related
- 1995-08-01 EP EP95112104A patent/EP0699440B1/en not_active Expired - Lifetime
- 1995-08-01 ES ES95112104T patent/ES2124477T3/es not_active Expired - Lifetime
- 1995-08-01 AT AT95112104T patent/ATE173626T1/de not_active IP Right Cessation
- 1995-08-05 KR KR1019950024260A patent/KR960006915A/ko not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0699440B1 (en) | 1998-11-25 |
| CA2152693A1 (en) | 1996-02-06 |
| KR960006915A (ko) | 1996-03-22 |
| US5650404A (en) | 1997-07-22 |
| DE69506197D1 (de) | 1999-01-07 |
| DE69506197T2 (de) | 1999-04-15 |
| EP0699440A1 (en) | 1996-03-06 |
| ATE173626T1 (de) | 1998-12-15 |
| ES2124477T3 (es) | 1999-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW317500B (OSRAM) | ||
| US5003098A (en) | Method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug | |
| EP0252227B1 (en) | Use of inositol triphosphate in the treatment of metal intoxication | |
| RU2272620C2 (ru) | Способы снижения пролиферации клеток на основе (3r,4r)△8 - тетрагидроканнабинол-11-оновых кислот (кислот из конопли) | |
| Hilgard et al. | Characterization of the antitumor activity of hexadecylphosphocholine (D 18506) | |
| JPH02108636A (ja) | 抗腫瘍性組合せ製剤 | |
| US5015634A (en) | Method of treating tissue damage with inositol triphosphate | |
| DE60219174T2 (de) | Mikronährstoff-phosphate als nahrungsergänzungsmittel und mittel zur förderung der gesundheit | |
| HU203201B (en) | Process for producing antitumoural pharmaceutical composition having synergetic effect | |
| EP1477166A1 (de) | Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis | |
| ES2309021T3 (es) | Fosfatidil-l-serina y acido fosfatidico para tratar la depresion y aliviar el estres. | |
| JPH09501653A (ja) | 薬学的組成物 | |
| US5057507A (en) | Method of alleviating bone damage with inositoltriphosphate | |
| GB2223167A (en) | The treatment of tissue damage | |
| EP0390574A2 (en) | Compositions of phytic acid, and pharmaceutical uses thereof | |
| US20070009590A1 (en) | Physiologically active composition based on phosphatidylserine | |
| IL143751A (en) | Phospholipid complexes of proanthocyanidin A2 that act as anti-atherosclerotic substances | |
| KR20040049248A (ko) | Ν-바니릴 지방산 아미드를 포함하는 항종양 의약조성물-바니릴 지방산 아미드를 포함하는 항종양 의약조성물 | |
| US4626527A (en) | Process for utilizing choline to sustain muscular performance | |
| US5284835A (en) | Use of dilinoleoylphosphatidylcholine (DLPC) for treatment and prevention of cirrhosis and fibrosis in the liver | |
| JP2002527472A (ja) | 消化不良の処置 | |
| AU4559000A (en) | Antioxidative vitamin b6 analogs | |
| JPH01233219A (ja) | 制癌剤組成物 | |
| KR20070085496A (ko) | 알코올 남용, 간염, 췌장염의 예후의 치료 제제 | |
| JPS63267716A (ja) | 尿素サイクル代謝異常症治療剤 |